Novan’s Phase 3 Molluscum Pivotal Program Completes Enrollment
13 août 2019 08h15 HE
|
Novan, Inc.
MORRISVILLE, N.C., Aug. 13, 2019 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (Nasdaq:NOVN) today announced that the Company has recently completed patient recruitment in the Company’s...
Novan’s Drug Substance Demonstrates Inhibition of HPV-18 Virus Production
24 juil. 2019 08h30 HE
|
Novan, Inc.
Preclinical data published in Antiviral ResearchStudy conducted by Drs. N.S. Banerjee, L.T. Chow and T.R. Broker at The University of Alabama at BirminghamFindings reinforce anti-viral mechanism of...
Novan SB206 Phase 3 Molluscum Pivotal Program Update
11 juil. 2019 08h15 HE
|
Novan, Inc.
More than 50 percent of total expected patients now enrolledVirtually all of the clinical sites now active Discipline and execution focus remain of equal importance to recruitment activity ...
First Patient Enrolled and Dosed in Novan’s SB206 Phase 3 Molluscum Program
04 juin 2019 06h30 HE
|
Novan, Inc.
Phase 3 pivotal program commences and underwayInvestigative sites now activated and enrollment activities actionedAnticipated patient demand managed with a highly disciplined approach to trial...
Novan to Present Clinical Data at Annual Meeting of the Society for Investigative Dermatology
07 mai 2019 16h15 HE
|
Novan, Inc.
MORRISVILLE, N.C., May 07, 2019 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (NASDAQ:NOVN) today announced that recent data from the Company’s Phase 1b trial with SB414 cream for the...
Novan Completes Funding Transaction with Ligand Pharmaceuticals
06 mai 2019 09h00 HE
|
Novan, Inc.
Novan to immediately receive $12 million of non-dilutive capitalLigand to receive milestones and tiered royalty for North America SB206 molluscum indicationPhase 3 molluscum trial to begin recruitment...
Novan Secures Up to $35 Million in Non-Dilutive Funding
29 avr. 2019 16h15 HE
|
Novan, Inc.
$25 million provided immediately in exchange for participation in future potential cash flows Additional $10 million available upon achieving success in molluscum Phase 3 top line resultsPipeline...
Novan and Sato Advance Japan Market and Dermatology Partnership
19 mars 2019 09h00 HE
|
Novan, Inc.
Dr. Elizabeth Messersmith named chairperson of the Sato and Novan Joint CommitteeSimultaneous clinical development progress for SB206 in Japan and US underwayNovan receives second installment of $4.5...
Novan Completes End-of-Phase 2 Meeting and Provides Additional Business Updates
11 mars 2019 08h00 HE
|
Novan, Inc.
Completed end-of-Phase 2 FDA meeting for molluscum contagiosumMeeting minutes received and support second quarter 2019 pivotal Phase 3 initiationFinalizing establishment of Irish entity to enable EU...
Novan Provides Business Update
30 janv. 2019 16h15 HE
|
Novan, Inc.
End-of-Phase 2 meeting with FDA for molluscum granted and scheduled for early MarchActive business development discussions ongoing around certain late-stage assets and broader dermatology platformDr....